Keywords: XOMA, Insulin receptor-regulating antibodies, Vivus, Qnexa, Diabetes, Weight loss, ADA meeting

ADA meeting hears news of XOMA’s new classes of insulin receptor-regulating Ab and Vivus’ Qnexa

Article | 27 June 2011

Print This

US therapeutic antibody discovery firm XOMA (Nasdaq: XOMA) presented results from its discovery of two new classes of fully human ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in